PRLD compared with SPRY: revenue, margins and what each company keeps, and the suppliers and customers both name

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

SPRYARS Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

PRLDPrelude Therapeutics Inc

SPRYARS Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

SPRY

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±22.2%▼−7.38%×0.33

May 15 '26±11.3%▼−6.49%×0.58

= impliedPRLD realized, solidSPRY realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

Q1 FY26

±22.8%

▼−0.11%

×0.00

Q3 FY25±18.0%▲+0.34%×0.02

PRLDPrelude Therapeutics Inc

3.89▼−5.01%· post 3.89

Mkt cap$309.6MRevenue$6MQ2 FY26Revenue—

SPRYARS Pharmaceuticals, Inc.

3.37▼−8.06%· post 3.37

ClosedOct 30 '26

Mkt cap$336.1MRevenue$34MQ2 FY26Revenue$84MFY25

Compare

ClosedOct 30 '26

PRLDPrelude Therapeutics Inc

SPRYARS Pharmaceuticals, Inc.

3.89▼−5.01%post 3.89

Price

3.37▼−8.06%post 3.37

$309.6M

Mkt cap

$336.1M

Q2 FY26$6M

Revenue

$34MQ2 FY26

—

Revenue

$84MFY25

PRLD3.89▼−5.01%vsSPRY3.37▼−8.06%ClosedOct 30 '26